Get the Stockscreener App
2.81
11.51%
0.29
Pre-market:
2.80
-0.01
-0.36%
Sana Biotechnology Inc stock is traded at $2.81, with a volume of 5.16M.
It is up +11.51% in the last 24 hours and up +61.03% over the past month.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
See More
Previous Close:
$2.52
Open:
$2.56
24h Volume:
5.16M
Relative Volume:
1.36
Market Cap:
$656.37M
Revenue:
-
Net Income/Loss:
$-283.26M
P/E Ratio:
-1.9116
EPS:
-1.47
Net Cash Flow:
$-273.61M
1W Performance:
-3.44%
1M Performance:
+61.03%
6M Performance:
+47.12%
1Y Performance:
-53.17%
1-Day Range:
$2.53
$2.85
1-Week Range:
$2.41
$3.015
52-Week Range:
$1.26
$7.40
Sana Biotechnology Inc Stock (SANA) Company Profile
Name
Sana Biotechnology Inc
Sector
Industry
Phone
(206) 701-7914
Address
188 EAST BLAINE STREET, SUITE 400, SEATTLE
Compare SANA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
2.81 | 656.37M | 0 | -283.26M | -273.61M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Nov-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-26-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-25-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Aug-14-23 | Initiated | TD Cowen | Market Perform |
| May-02-23 | Initiated | H.C. Wainwright | Neutral |
| Mar-01-21 | Initiated | BofA Securities | Buy |
| Mar-01-21 | Initiated | Goldman | Neutral |
| Mar-01-21 | Initiated | JP Morgan | Neutral |
| Mar-01-21 | Initiated | Morgan Stanley | Overweight |
View All
Sana Biotechnology Inc Stock (SANA) Latest News
Investigation announced for long-term Investors in shares - openPR.com
Pallas Capital Advisors LLC Makes New $29,000 Investment in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Sana Biotechnology (NASDAQ:SANA) versus Mosaic ImmunoEngineering (OTCMKTS:CPMV) Critical Analysis - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 25,383 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Lead Plaintiff Appointed in Sana Biotechnology Class Action — Here’s How You Can Recover Your Losses - TradingView
Paysign Leads Our Trio Of Penny Stock Highlights - simplywall.st
Transcript : Sana Biotechnology, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - marketscreener.com
Sana Biotechnology to present at 85th annual American Diabetes Association Scientific Sessions - marketscreener.com
Sana Biotechnology to Present First-in-Human Clinical Data on Hypoimmune Islet Cell Therapy for Type 1 Diabetes at ADA Scientific Sessions - Nasdaq
Sana Biotechnology Announces Invited Oral Presentation at - GlobeNewswire
Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes ... - Bluefield Daily Telegraph
Sana Bio to Present Novel Immunosuppression-Free Diabetes Cell Therapy Data at ADA | SANA Stock News - Stock Titan
Shareholders Filed a Lawsuit Against $SANA for Misleading Investors About Financial Health - TradingView
Two Sigma Investments LP Grows Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Ameriprise Financial Inc. Invests $29,000 in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Squarepoint Ops LLC Buys 55,625 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Sana Biotechnology Elects Directors at Annual Meeting - TipRanks
Transcript : Sana Biotechnology, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 02 - marketscreener.com
Sana Biotechnology, Inc. (NASDAQ:SANA) Stock Position Raised by Two Sigma Advisers LP - Defense World
Nuveen Asset Management LLC Sells 27,104 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Biggest Stocks in NASDAQ Featuring Sana Biotechnology and Kalkine - Kalkine Media
Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Purchased by Millennium Management LLC - Defense World
BNP Paribas Financial Markets Makes New Investment in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Bank of America Corp DE Increases Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
ProShare Advisors LLC Grows Stock Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Rosen, Pomerantz To Lead Seattle Biotech Class Action - Law360
Are Investors Declined To Sell Their Sana Biotechnology Inc (NASDAQ: SANA) Holdings? - Stocksregister
Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Deutsche Bank AG Sells 72,413 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Sana Biotechnology Reveals Latest Cell Therapy Progress at Jefferies and Goldman Sachs Healthcare Conferences - Stock Titan
Sana Biotechnology to Present at June 2025 Investor Conferences - GlobeNewswire
Jane Street Group LLC Boosts Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Sana Biotechnology’s SWOT analysis: engineered cell stock faces pivotal year By Investing.com - Investing.com South Africa
Northern Trust Corp Buys 60,004 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Sana Biotechnology’s SWOT analysis: engineered cell stock faces pivotal year - Investing.com Nigeria
Focus Partners Wealth Takes Position in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Securities Lawsuit Alert: Sana Biotechnology, Inc. (SANA)Contact Levi & Korsinsky Before May 20, 2025 - ACCESS Newswire
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Sana Biotechnology, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before May 20, 2025 to Discuss Your RightsSANA - The Malaysian Reserve
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain OfficersSANA - PR Newswire
Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc.(SANA) of a Class Action Lawsuit and an Upcoming Deadline - Morningstar
Contact Levi & Korsinsky by May 20, 2025 to Join Class Action Against Sana Biotechnology, Inc. (SANA) - ACCESS Newswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology - StreetInsider
Sana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes Treatment - Seeking Alpha
Shareholders of Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, ... - Eagle-Tribune
SANA DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, - GlobeNewswire
The End Of The Diabetes Industry?Eli Lilly (NYSE:LLY), DexCom (NASDAQ:DXCM) - Benzinga
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Sana Biotechnology, Inc. (SANA) Investors of May 20, 2025 Deadline - ACCESS Newswire
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm - marketscreener.com
Sana Biotechnology Inc Stock (SANA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):